Efficacy and safety of quercetin and polyvinylpyrrolidone in treatment of patients with newly diagnosed destructive pulmonary tuberculosis in comparison with standard antimycobacterial therapy

• Main Authors: Dmytro Butov, Svetlana Zaitseva, Tatyana Butova, Ganna Stepanenko, Olga Pogorelova, Natalia Zhelezniakova
• Format: Article
• Language: English
• Published: Wolters Kluwer Medknow Publications 2016-01-01
• Series: International Journal of Mycobacteriology
• Subjects: Immunotherapy; Quercetin; Quercetin and polyvinylpyrrolidone; Treatment of tuberculosis; Tuberculosis
• Online Access: http://www.ijmyco.org/article.asp?issn=2212-5531;year=2016;volume=5;issue=4;spage=446;epage=453;aulast=Butov

Objective/background: The objective/background of this work was to study the efficacy and safety of quercetin and polyvinylpyrrolidone (QP) in the treatment of patients with newly diagnosed destructive pulmonary tuberculosis in comparison with standard antimycobacterial therapy. Materials and methods: The study involved 124 patients aged between 20 years and 70 years with newly diagnosed destructive pulmonary tuberculosis. Patients were allocated to two groups. The first (control) group of patients received standard antimycobacterial and pathogenetic therapy and included 31 (25.00±3.89%) patients. The second (main) group of patients received QP therapy in addition to chemotherapy and included 93 (75.00±3.89%) patients. Results: Intoxication symptoms in the second group were reduced following 1.33±0.15 months, whereas in the first group intoxication symptoms were reduced following 2.64±0.20 months, p < .001. Conclusion: Administration of QP combined with chemotherapy in patients with newly diagnosed destructive pulmonary tuberculosis resulted in a comparatively quick reduction of disease manifestation.